Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues in tumors expressing somatostatin receptors
2013-002605-65Phase 2Completed
- Sponsor
- Santa Maria Nuova
- Start
- Oct 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium Lu 177 dotatate and 90Y-DOTATATE in apudoma (NET) and cancer (2 arms), sponsored by Santa Maria Nuova. Primary endpoints: Survival at 3 and 6 months and Progression-free survival (PFS). Started Oct 2013; status: completed.
02
Drugs
lutetium Lu 177 dotatate90Y-DOTATATE
03
Conditions
apudoma (NET)cancer
Beyond the preview
Go deeper on 2013-002605-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002605-65.